News Archive

found Documents:402

Regulatory Notice, RNS Announcements | 5 Feb 2018

Chi-Med to Announce 2017 Final Results

1 item

London: Monday, February 5, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its final results for the year ended December 31, 2017 on Monday, March 12, 2018 at 7:00 am Greenwich Mean Time (GMT). An analy

Download Announcement (PDF)

Regulatory Notice, RNS Announcements | 29 Dec 2017

Total Voting Rights

1 item

London: Friday, December 29, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 29, 2017, the issued share capital of Chi-Med consisted of 66,447,037 ordin

Download Announcement (PDF)

Regulatory Notice, RNS Announcements | 29 Dec 2017

Blocklisting Six Monthly Return

1 item

London: Friday, December 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: H

Download Announcement (PDF)

Innovation Platform, Press Releases, RNS Announcements | 15 Dec 2017

Chi-Med Initiates Fruquintinib U.S. Clinical Trials

1 item

London: Friday, December 15, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated the United States Phase I bridging clinical trial of fruquintinib. Fruquintinib is a highly selective and potent oral inhibitor of vas

Download Press Release (PDF)

Regulatory Notice, RNS Announcements | 1 Nov 2017

TR-1: Notification of major interest in shares

1 item

Download Announcement (PDF)

Regulatory Notice, RNS Announcements | 1 Nov 2017

TR-1: Notification of major interest in shares

1 item

Download Announcement (PDF)

Innovation Platform, Press Releases, RNS Announcements | 31 Oct 2017

Chi-Med Initiates FRUTIGA, a Phase III Trial of Fruquintinib in Second-Line Gastric Cancer

1 item

London: Tuesday, October 31, 2017: Hutchison China MediTech Limited (“Chi‑Med”) (AIM/Nasdaq: HCM) has initiated FRUTIGA, a pivotal Phase III clinical trial of fruquintinib in combination with paclitaxel (Taxol®) for the treatment in advanced g

Download Press Release (PDF)

Group, RNS Announcements | 30 Oct 2017

Chi-Med Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately US$301.3 Million on the Nasdaq Global Select Market

1 item

London: Monday, October 30, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today the closing of its underwritten public offering of American Depositary Shares ("ADSs") on the Nasdaq Global Select Market, previously

Download Announcement (PDF)

Group, RNS Announcements | 27 Oct 2017

Chi-Med Announces the Full Exercise of Underwriters' Over-allotment Option

1 item

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Friday, October 27, 2017: Hutchison China MediTech L

Download Announcement (PDF)

Group, RNS Announcements | 26 Oct 2017

Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market (RNS)

1 item

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Wednesday, October 25, 2017: Hutchison China MediTec

Download Announcement (PDF)

Group, RNS Announcements | 25 Oct 2017

Chi-Med Announces Proposed Offering of ADSs (RNS)

1 item

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Tuesday, October 24, 2017: Hutchison China MediTech

Download Full Announcement (PDF, 87 pages including Appendix)

Regulatory Notice, RNS Announcements | 19 Oct 2017

TR-1: Notification of major interest in shares

1 item

Download Announcement (PDF)

Innovation Platform, Press Releases, RNS Announcements | 17 Oct 2017

Chi-Med and AstraZeneca’s Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET-Amplification

1 item

– Data for savolitinib in combination with Tagrisso® or Iressa® presented at World Conference on Lung Cancer – – New data give insights into disease progression and potential next-generation treatment strategies in patients with EGFR-muta

Download Announcement (PDF)

Innovation Platform, Press Releases, RNS Announcements | 16 Oct 2017

Chi-Med Reports Preliminary Phase II data on Fruquintinib Combination in First-Line Lung Cancer

1 item

Press Release – Fruquintinib in combination with Iressa® (gefitinib) shows promising efficacy and an acceptable safety profile – – Further validation of strong potential for use of fruquintinib in combination with other cancer therapies du

Downoad Press Release (PDF)

Group, Press Releases, RNS Announcements | 12 Oct 2017

Chi-Med Appoints Professor Tony Mok to Board of Directors

1 item

Appointment of Director London: Thursday, October 12, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Professor Mok, Shu Kam Tony has been appointed as Independent Non-Executive Director and member of t

Download Announcement (PDF)

Innovation Platform, Press Releases, RNS Announcements | 29 Sep 2017

Chi-Med Highlights Oral Presentations at CSCO Annual Meeting

1 item

Press Release – Three oral presentations given at CSCO for fruquintinib, savolitinib and theliatinib – – Plenary keynote presentation for FRESCO Phase III trial details analysis showing consistent survival benefit in all key subgroups

Download Press Release (PDF)

Innovation Platform, Press Releases, RNS Announcements | 29 Sep 2017

Chi-Med to Present Savolitinib and Fruquintinib Clinical Data at WCLC 2017 Annual Meeting

1 item

Press Release – Data to show potential of savolitinib to treat EGFR-TKI resistance in both Iressa® and Tagrisso® refractory patients with MET amplification – – Results to further validate Chi-Med’s scientific strategy of designing highly

Download Press Release (PDF)

Regulatory Notice, RNS Announcements | 29 Sep 2017

Total Voting Rights

1 item

London: Friday, September 29, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at September 29, 2017, the issued share capital of Chi-Med consisted of 60,750,132 ord

Download Announcement (PDF)

Regulatory Notice, RNS Announcements | 31 Aug 2017

Director's Share Dealing

1 item

London: Thursday, August 31, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated with Mr To,

Download Announcement (PDF)

Innovation Platform, Press Releases, RNS Announcements | 29 Aug 2017

Chi‑Med Initiates a Phase I Clinical Trial of Selective PI3Kδ Inhibitor HMPL‑689 in Lymphoma Patients in China

1 item

Press Release London: Tuesday, August 29, 2017: Hutchison China MediTech Limited (“Chi‑Med”) (AIM/Nasdaq: HCM) has initiated a Phase I clinical trial of HMPL‑689 in China. HMPL-689 is a novel, highly selective and potent small molecule inhib

Download Press Release (PDF)

Regulatory Notice, RNS Announcements | 22 Aug 2017

Director's Share Dealing

1 item

London: Tuesday, August 22, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 4,000 American Depositary Shares of

Download Announcement (PDF)

Regulatory Notice, RNS Announcements | 18 Aug 2017

Directors' Share Dealing

1 item

London: Friday, August 18, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- (a) Mr Simon To, Executive Director and Chairman, through Wencheng Capital Limited (“WCL”), a person closely

Download Announcement (PDF)

Regulatory Notice, RNS Announcements | 15 Aug 2017

Directors' Share Dealing

1 item

London: Tuesday, August 15, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- (a) Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated (�

Download Announcement (PDF)

Regulatory Notice, RNS Announcements | 10 Aug 2017

Director’s Share Dealing

1 item

London: Thursday, August 10, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notifications that Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 1,807 American Depositary Shares of th

Download Announcement (PDF)

Regulatory Notice, RNS Announcements | 7 Aug 2017

Directors' Share Dealing

1 item

London: Monday, August 7, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- (a) Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated (“P

Download Announcement (PDF)

Group, RNS Announcements | 31 Jul 2017

Chi-Med Reports 2017 Interim Results and Updates Shareholders on Key Clinical Programs

1 item

London: Monday, July 31, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM), the China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the glob

View Announcement (PDF)

Regulatory Notice, RNS Announcements | 30 Jun 2017

Total Voting Rights

1 item

London: Friday, June 30, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at June 30, 2017, the issued share capital of Chi-Med consisted of 60,737,204 ordinary shar

Download Announcement (PDF)

Innovation Platform, Press Releases, RNS Announcements | 29 Jun 2017

Chi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma

1 item

AstraZeneca PLC (“AstraZeneca”) (LON/STO/NYSE: AZN) Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) London: Thursday, June 29, 2017: Chi-Med and AstraZeneca today announce that they have initiated

Download Announcement (PDF)

Regulatory Notice, RNS Announcements | 29 Jun 2017

Blocklisting Six Monthly Return

1 item

London: Thursday, June 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of sc

Download Announcement (PDF)

Group, Press Releases, RNS Announcements | 29 Jun 2017

Chi-Med to Announce 2017 Half-Year Financial Results

1 item

London: Thursday, June 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2017 on Monday, July 31, 2017 at 7:00 am British Summer Time (BST). An ana

Download Announcement (PDF)

Innovation Platform, Press Releases, RNS Announcements | 22 Jun 2017

Chi-Med Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL-453 in China

1 item

Press Release London: Thursday, June 22, 2017: Hutchison China MediTech Limited (“Chi‑Med”) (AIM/Nasdaq: HCM) has just initiated a Phase I/II clinical trial of HMPL‑453 in China. HMPL‑453 is a novel, highly selective and potent small mol

Download Press Release (PDF)

Regulatory Notice, RNS Announcements | 16 Jun 2017

Director’s Share Dealing

1 item

London: Friday, June 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- Dynamic Drive Limited, a person closely associated (“PCA”) with Mr Simon To, Executive Director and Chairma

Download Announcement (PDF)

Innovation Platform, Press Releases, RNS Announcements | 12 Jun 2017

Chi-Med Submits New Drug Application to CFDA for Fruquintinib in Advanced Colorectal Cancer

1 item

– Application accepted by CFDA for technical review by the Center for Drug Evaluation – – Triggers RMB30.8 million milestone payment from Eli Lilly and Company (“Lilly”) – London: Monday, June 12, 2017: Hutchison China MediTech L

Download Announcement (PDF)

Innovation Platform, Press Releases, RNS Announcements | 5 Jun 2017

Chi-Med Highlights Phase III Fruquintinib Data in Oral Presentation at ASCO

1 item

Press Release Chicago: Monday, June 5, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced that results from its pivotal Phase III trial with fruquintinib, its novel vascular endothelial growth factor receptor (“VEGF

Download Press Release (PDF)

Innovation Platform, Press Releases, RNS Announcements | 18 May 2017

Chi-Med Presents Clinical Data at ASCO 2017 Annual Meeting

1 item

Press Release – FRESCO Phase III trial results for fruquintinib in colorectal cancer in an oral presentation – – Five abstracts in total accepted for fruquintinib, savolitinib and sulfatinib – London: Thursday, May 18, 2017: Hutchison Chin

Download Press Release (PDF)

Regulatory Notice, RNS Announcements | 28 Apr 2017

Total Voting Rights

1 item

London: Friday, April 28, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at April 28, 2017, the issued share capital of Chi-Med consisted of 60,735,104 ordinary sh

View Announcement (PDF)

Regulatory Notice, RNS Announcements | 27 Apr 2017

Results of Annual General Meeting

1 item

London: Thursday, April 27, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting (“AGM”) held on April 27, 2017 were duly

View Announcement (PDF)

Innovation Platform, Press Releases, RNS Announcements | 7 Apr 2017

Chi-Med Presented Pre-clinical Data for Fruquintinib and Sulfatinib at the American Association for Cancer Research Annual Meeting 2017

1 item

London: Friday, April 7, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) presented pre-clinical data for fruquintinib and sulfatinib at the American Association for Cancer Research (“AACR”) Annual Meeting 2017, held in Wa

Download Press Release (PDF)

Regulatory Notice, RNS Announcements | 31 Mar 2017

Total Voting Rights

1 item

London: Friday, March 31, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at March 31, 2017, the issued share capital of Chi-Med consisted of 60,715,323 ordinary sh

Download Announcement (PDF)

Regulatory Notice, RNS Announcements | 29 Mar 2017

Vesting of awards under the Long Term Incentive Plan

1 item

Download Announcement (PDF)

Regulatory Notice, RNS Announcements | 28 Mar 2017

Grant of Share Options under Share Option Scheme

1 item

London: Tuesday, March 28, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on March 27, 2017, it granted share options under the Share Option Scheme adopted by Chi-Med at its Annual General Meeting on April 24,

View Announcement (PDF)

Group, RNS Announcements | 27 Mar 2017

2016 Annual Report and Notice of Annual General Meeting

1 item

London: Monday, March 27, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its 2016 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders.

a170327

Group, Press Releases, RNS Announcements | 24 Mar 2017

Chi-Med Appoints Weiguo Su, Chief Scientific Officer, to Board of Directors

1 item

Appointment of Director London: Friday, March 24, 2017: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) today announces that Dr Weiguo Su has been appointed as Executive Director and member of Technical Commi

Download Announcement (PDF)

Innovation Platform, Press Releases, RNS Announcements | 21 Mar 2017

Chi-Med to host R&D Briefings on March 29 & 30, 2017

1 item

Press Release London: Tuesday, March 21, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it will host Research & Development (“R&D”) briefings in London and New York to provide an overview o

Download Press Release (PDF)

Regulatory Notice, RNS Announcements | 20 Mar 2017

Directors’ Share Dealing

1 item

London: Monday, March 20, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- Mr Paul Carter, Independent Non-executive Director, purchased a total of 2,800 ordinary shares of US$1.00 each in

Download Announcement (PDF)

Group, Press Releases, RNS Announcements | 16 Mar 2017

Grant of Awards under Long Term Incentive Plan

1 item

Press Release London: Thursday, March 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on March 15, 2017, it granted conditional awards (“LTIP Awards”) under the Long Term Incentive Plan (“LTIP”) a

Download Press Release (PDF)

Group, RNS Announcements | 13 Mar 2017

Publication of Form 20-F for the Year Ended December 31, 2016

1 item

London: Monday, March 13, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today published the Form 20-F for the financial year ended December 31, 2016 per attached and also available for viewing on the Company's website at ww

View Form 20-F (PDF)

Group, RNS Announcements | 13 Mar 2017

Chi-Med Reports Final Results for the Year Ended December 31, 2016 and Updates on Key Clinical Programs

1 item

Hutchison China MediTech Limited (“Chi-Med”) Reports Final Results for the Year Ended December 31, 2016 and Updates Shareholders on Key Clinical Programs Group: Record revenue, net income and clinical investment in 2016 Group revenue up 21%

View Full Announcement (PDF)

Innovation Platform, Press Releases, RNS Announcements | 10 Mar 2017

Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference of the European Neuroendocrine Tumor Society

1 item

Press Release London: Friday, March 10, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) presented data from the ongoing Phase Ib/II clinical trial of sulfatinib in patients with advanced neuroendocrine tumors (“NET”) at

Download Press Release (PDF)

Innovation Platform, RNS Announcements | 3 Mar 2017

Chi-Med Announces Positive Top-Line Results for FRESCO, its Phase III Pivotal Registration Trial of Fruquintinib in Patients with Locally Advanced or Metastatic Colorectal Cancer

1 item

– Trial met all primary and secondary endpoints – – Safety as expected – – Progressing to China NDA submission mid-2017 – – Full data to be reported at an upcoming scientific meeting in mid-2017 – London: Friday, March 3, 2017: Hu

Download Announcement (PDF)

3 4 5 6 7 8 9